ABSTRACT
Background and Aims Individuals who report meeting weekly moderate to vigorous physical activity (MVPA) guidelines have lower risk of atrial fibrillation (AF). However existing studies have relied on subjective questionnaires or short-duration (<1 week) objective assessments using accelerometry. The objective of this research was to investigate an association between moderate to vigorous physical activity (MVPA) levels and the incidence of atrial fibrillation (AF), utilizing long-term, free-living accelerometry data.
Methods 1-year Fitbit data, in addition to survey and electronic health record (EHR) data, were extracted from the NIH All of Us (AoU) research database. Cox proportional hazards regression was used to model the association of average MVPA (both continuous and categorized as <30, 30-150,151-300, and >300 minutes/week) and incident AF over a five-year follow-up period.
Results 6086 AoU participants were included (51±16 years, 70% female, 83% White, BMI 28.5±4.9 kg/m2, 41±12 complete weeks of Fitbit wear). 55 individuals (0.9%) experienced incident AF in the five-year follow-up period. More time spent in MVPA was associated with lower AF risk (HR = 0.89 [0.81,0.98], p=0.02), with a step-wise reduction for 151-300 mins (p=0.07) and >300 mins (p=0.04) of weekly MVPA, respectively. In a subset of 3847 participants with genomic data, this association persisted after adjustment for AF genetic risk score.
Conclusions Higher amounts of objectively measured MVPA, measured using free-living, long-term accelerometry data, were inversely associated with risk of incident AF, independent of clinical and genetic risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was partially supported by the Abramson-Stires award from the NYU Grossman School of Medicine Department of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in this study are available to the public via All of Us.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Primary Author
Data Availability
To ensure privacy of participants, data used for this study are available to approved researchers following registration, completion of ethics training and attestation of a data use agreement through the All of Us Research Workbench platform, which can be accessed via https://workbench.researchallofus.org/login. Code used for this study can be made available to users of the All of Us Research Workbench platform by contacting our study team. Contact email: Souptik.Barua{at}nyulangone.org
